219 related articles for article (PubMed ID: 26990144)
1. Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure.
Mori T; Ohsaki Y; Oba-Yabana I; Ito S
Hepatol Res; 2017 Jan; 47(1):11-22. PubMed ID: 26990144
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of congestive heart failure with concomitant administration of tolvaptan to enhance the effects of furosemide.
Nishizaki Y; Yamagami S; Sesoko M; Yamashita H; Daida H
J Cardiol Cases; 2013 Nov; 8(5):151-154. PubMed ID: 30546768
[TBL] [Abstract][Full Text] [Related]
3. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
4. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095
[TBL] [Abstract][Full Text] [Related]
5. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
6. [Value of aldosterone receptor blockade in diuretic therapy of patients with chronic heart failure].
Christ M; Ludwig N; Maisch B
Herz; 2002 Mar; 27(2):135-49. PubMed ID: 12025459
[TBL] [Abstract][Full Text] [Related]
7. Long-term administration of tolvaptan increases myocardial remodeling and mortality via exacerbation of congestion in mice heart failure model after myocardial infarction.
Eguchi A; Iwasaku T; Okuhara Y; Naito Y; Mano T; Masuyama T; Hirotani S
Int J Cardiol; 2016 Oct; 221():302-9. PubMed ID: 27404696
[TBL] [Abstract][Full Text] [Related]
8. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
[TBL] [Abstract][Full Text] [Related]
9. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
[TBL] [Abstract][Full Text] [Related]
10. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.
Jujo K; Saito K; Ishida I; Furuki Y; Kim A; Suzuki Y; Sekiguchi H; Yamaguchi J; Ogawa H; Hagiwara N
ESC Heart Fail; 2016 Sep; 3(3):177-188. PubMed ID: 27818782
[TBL] [Abstract][Full Text] [Related]
11. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis.
Mori T; Oba I; Koizumi K; Kodama M; Shimanuki M; Tanno M; Chida M; Saito M; Kiyomoto H; Miyazaki M; Ogawa S; Sato H; Ito S
Adv Perit Dial; 2013; 29():33-7. PubMed ID: 24344488
[TBL] [Abstract][Full Text] [Related]
12. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
[TBL] [Abstract][Full Text] [Related]
13. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure.
Otsuka T; Sakai Y; Ohno D; Murasawa T; Sato N; Tsuruoka S
Clin Exp Nephrol; 2013 Dec; 17(6):834-8. PubMed ID: 23483323
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of tolvaptan in a patient with right-sided heart failure and renal dysfunction refractory to diuretic therapy.
Joko Y; Ikemura N; Miyata K; Shiraishi Y; Tanaka H; Yoshida T; Ikegami Y; Fuse J; Sakamoto M; Momiyama Y
J Cardiol Cases; 2014 Jun; 9(6):226-229. PubMed ID: 30534332
[TBL] [Abstract][Full Text] [Related]
15. Different diuretic properties between tolvaptan and furosemide in congestive heart failure patients with diuretic resistance and renal impairment: a subanalysis of the K-STAR.
Ikeda Y; Inomata T; Kida K; Shibagaki Y; Sato N; Izumi T; Ako J;
Heart Vessels; 2019 Mar; 34(3):442-451. PubMed ID: 30259172
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
Matsuzaki M; Hori M; Izumi T; Fukunami M;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
[TBL] [Abstract][Full Text] [Related]
17. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction.
Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
J Card Fail; 2016 Jun; 22(6):423-32. PubMed ID: 26915749
[TBL] [Abstract][Full Text] [Related]
18. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment - Results From the K-STAR Study.
Inomata T; Ikeda Y; Kida K; Shibagaki Y; Sato N; Kumagai Y; Shinagawa H; Ako J; Izumi T;
Circ J; 2017 Dec; 82(1):159-167. PubMed ID: 28835586
[TBL] [Abstract][Full Text] [Related]
19. Tolvaptan in a pediatric patient with diuretic-resistant heart and kidney failure.
Hirano D; Kakegawa D; Yamada A; Ito A; Miwa S; Ida H
Pediatr Int; 2015; 57(1):183-5. PubMed ID: 25711263
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients.
Tanaka A; Katsuno T; Ozaki T; Sakata F; Kato N; Suzuki Y; Kosugi T; Kato S; Tsuboi N; Sato W; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
Acta Cardiol; 2015 Apr; 70(2):217-23. PubMed ID: 26148383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
